Meena Kannan, MD
Neurology · Charlottesville, VANPI 1841589249
Payments from drug & device makers
Across 47 payments — averaging $117.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$4K
- EMD Serono, Inc.$470
- Genentech USA, Inc.$157
- Sanofi$141
- Bristol Myers Squibb$111
- Amgen$106
- plus $526 from 15 others
What the payments were for
- Food & beverage$1,42988%
- Education$18812%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 6 | $4,030 |
| EMD Serono, Inc. | 8 | $470 |
| Genentech USA, Inc. | 1 | $157 |
| Sanofi | 2 | $141 |
| Bristol Myers Squibb | 5 | $111 |
| Amgen | 4 | $106 |
| AstraZeneca | 1 | $100 |
| Novartis | 5 | $81 |
| Catalyst Pharmaceuticals, Inc. | 2 | $49 |
| Genentech, Inc. | 1 | $40 |
| AbbVie | 2 | $29 |
| Lundbeck LLC | 1 | $29 |
| Argenx US, Inc. | 1 | $29 |
| Neurocrine Biosciences, Inc. | 1 | $28 |
| Invivyd Inc | 1 | $27 |
| Mallinckrodt Hospital Products Inc. | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Immedica Pharma US, Inc. | 1 | $20 |
| Impel Pharmaceuticals Inc. | 1 | $19 |
| Octapharma USA, Inc. | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,542 in reported general payments places this provider in the 65th percentile of 474 neurology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 17 | $180,306 |
| ZeposiaOzanimod Hydrochloride | 12 | $105,382 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 18 | $92,799 |
| Dalfampridine ErDalfampridine | 13 | $6,270 |
| Modafinil | 23 | $2,059 |
| Baclofen | 39 | $1,247 |
| Gabapentin | 47 | $769 |
| Escitalopram Oxalate | 16 | $242 |
| Tizanidine Hcl | 14 | $192 |
| Sodium Chloride0.9 % Sodium Chloride | 22 | $124 |
Paid to pharmacies, not to this prescriber.
Other neurology in Charlottesville
- Robert ShinCharlottesville$2.2M
- Nathan FountainCharlottesville$497K
- David SchiffCharlottesville$460K
- Xuemei HuangCharlottesville$410K
- Virginia SimnadCharlottesville$261K
- Nina SolenskiCharlottesville$212K
- Matthew ElliottCharlottesville$203K
- Andrew SoutherlandCharlottesville$198K
- Brian WeinshenkerCharlottesville$197K
- David LapidesCharlottesville$151K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.